Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

NEUROCRINE BIOSCIENCES INC Form 4 March 20, 2003

FORM 4

_ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response. . .0.5

Filed By

Romeo and Dye's

Section 16 Filer www.section16.net

OMB APPROVAL

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Ade Sherwin, Stephe	2. Issuer Name and Ticker or Trading Symbol Neurocrine Biosciences, Inc./NBIX							6. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) Cell Genesys, Inc. 500 Forbes Blvd.				of Reporting Person,				4. Statement for <u>X</u> Month/Day/Year 10 03/19/03		Director 0% Owner Officer (give title below) ther (specify below)		
South San Fran	(Street) cisco, CA 940)80					Date	Amendment, e of Original nth/Day/Year)	(C <u>X</u> Pe	heck Applicab Form filed by rson	One Reporting More than One	
(City)	(State) (Zip)	Г	able	e I Non-I	Derivat	tive Secu	urities Acquired, I	Dispose	d of, or Benef	icially Owned	
1. Title of Security	2. Trans- action Execution action or Disposed of (D) Date Date, Code (Instr. 3, 4 & 5) (Month/ Day/ if any (Instr. 8)				uired (A		•	6. Owner- ship Form: Direct (D) or Indirect (I) Ownership				
	Year)	(Month/Day/ Year)	Code	v	Amount	(A) or (D)	Price	ing Reported Transactions(s) (Instr. 3 & 4)		(Instr. 4)	(Instr. 4)	
Common Stock	03/19/03		Α		5,000	A	4.031	2	5,000	D		
Common Stock	03/19/03		S		5,000	D	44.23	5		D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number

FORM 4 (continued) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

ľ	1. Title of	2. Conver-	3. Trans-	3A.	4.	5.	6. Date Exercisable	7. Title and Amount of	8. Price of	9. Number of	10.
ľ	Derivative	sion or	action	Deemed	Trans-	Number	and Expiration	Underlying Securities	Derivative	Derivative	Owner-
ŀ	Security	Exercise	Date	Execution	action	of	Date	(Instr. 3 & 4)	Security	Securities	ship
	1 1	Price of	1 '	Date,	Code	Derivative	e(Month/Day/	1	(Instr. 5)	Beneficially	Form
1	(Instr. 3)	Derivative	(Month/	if any	1	Securities	Year)	1	1 '	Owned	of Deriv-
	1 1	1 '	1 '	1 '	1	1 '	1 '	1 '	1 '	1 '	1

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

S		Year)	(Month/ Day/ Year)	(Instr. 8)	(A) Dis of (posed					Reported	ative Security: Direct (D) or Indirect
				Code	4 & V (A)	(D)	Exer-cisable	Expira- tion Date		Amount or Number of Shares		(I) (Instr. 4)
atutory Option	4.0312	03/19/03		M ⁽¹⁾		5,000	05/22/99	04/22/09	Common Stock	5,000		D

Explanation of Responses:

(1) Exercise of derivative security exempted pursuant to Rule 16b-3.

By: /s/ Margaret E. Valeur-Jensen

<u>03/20/03</u> Date

**Signature of Reporting Person

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed.

If space is insufficient, See Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.